Endeavor v. Cypher
This article was originally published in The Gray Sheet
Executive Summary
Medtronic announces July 30 the start of the PROTECT trial comparing Medtronic's Endeavor zotarolimus-eluting stent to Johnson & Johnson's Cypher sirolimus-eluting stent. The 8,800-patient "real world" study will follow patients for three years, evaluating safety endpoints including stent thrombosis and myocardial infarction. At least 1,000 of the patients will be in the U.S